obesity drug news today glp-1 2025 sep 30 Agonists Weight Loss Drugs Market Report, 2025-2030 Use of diabetes and anti-obesity
Description
For Medicare beneficiaries on fixed incomes, this is the difference between access and impossibility
Knudsen was not the only one interested in obesity at Novo Nordisk
Things like fitness memberships and classes, nutrition programs, meal delivery services
At PSG, weve seen off-label GLP-1 spend reach as high as 50% among payers without tight utilization controls
We recommend assessing patients for GI symptoms attributable to GLP-1 receptor agonists, such as nausea, vomiting, dyspepsia, or changes in bowel habit
Most events were mild to moderate and occurred during dose escalation
